TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors
TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting
TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03
TScan Therapeutics Announces Positive Updated Data from the ALLOHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
Apex Extends Trinity Zone 200 m with 3.55% REO over 116.0 m and 2.35% over 171.5 m in Western Step-out Drilling at Rift
Goldera Expands High-Grade E1 Gold Discovery with Two New Parallel Structures Ahead of Planned Q4 Drilling at Egan Gold Project
Oreterra CEO Letter to Shareholders Provides Forward Guidance on Trek South Drill Results in Advance of Assays
LaFleur Minerals Intersects 6.05 g/t Au over 8.00 Metres, Including 14.96 g/t Au over 3.00 Metres, Near Surface at Bartec Target and Identifies Additional New Targets at the Swanson Property
